YATHARTHHealthcare

Yatharth Hospital & Trauma Care Services Limited

Hospital · ISIN INE0JO301016 · BSE 543950 · NSE EQ · FV ₹10
Last price
₹1,072
+9.17%today
What this company does

Yatharth Hospital & Trauma Care Services Limited operates in Hospital, part of the Healthcare sector. It booked ₹393 cr of revenue in its latest quarter (Q1 FY27) and kept 12.0% of sales as profit.

The company is engaged in the business of providing healthcare services, operating hospitals Income from hospital services comprises of fees and other allied services, as may be required for the charged for inpatient and outpatient hospital provision of healthcare services.
Their stated mission

to provide high-quality healthcare services while navigating the challenges posed by the evolving healthcare landscape.

In the report:
46out of 100
Equitytale Health Score
Mixed

Healthier than 46% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 33–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
overbought
RSI (14)
74

At close. Not part of the score.

Profitability & returns43

How much profit it earns on the money it employs

Balance sheet61

How much it owes, and whether earnings cover the interest

Cash quality26

Whether reported profit actually arrives as cash

Valuation34

What today's price implies, against our models or its peers

Governance & risk72

How much of the promoters' stake is pledged, and how much they hold

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 52% vs last year
Profit up 12% vs last year
Promoters hold 56%
Turns profit into real cash
Watch-outs
! 9.6% of promoter stake pledged

What if I invest in YATHARTH?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹1,072 +9.17%
latest close · 2026-09-17
52-wk low ₹81542 sessions so far52-wk high ₹1,084
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio54.9High
LowAverageHigh
P/B ratio5.72High
Below bookModerateHigh
EV / EBITDA27.0High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity10.4%Fair
WeakFairStrong ▸15%
Return on capital12.9%Fair
WeakFairStrong
Net margin12.0%Decent
ThinDecentStrong
EBITDA margin24.5%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.14Comfortable
LowModerateHigh ▸1
Interest cover10.3×Strong
RiskyOkayStrong ▸5×
Current ratio3.87Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹10,333 cr
Book value
₹188
EPS
₹4.88
latest quarter
Net debt
₹32 cr
owes more than its cash
Enterprise value
₹10,365 cr
EBITDA
₹384 cr
annualised
EBIT
₹271 cr
annualised
Operating margin
17.3%
Return on assets
8.3%
Earnings yield
1.82%
P/S
6.58
Sales / share
₹163.0
Tax rate
25.8%
Face value
₹10
Shares
9.6 cr
Working capital
₹528 cr
Current assets
₹712 cr
Current liabilities
₹184 cr
Delivery %
40.4%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2024 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹113₹239, midpoint ₹146

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹393 cr
Other Income₹4 cr
Total Income₹397 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹71 cr
Inventory Change (±)₹-2 cr
Employee Benefit Expense₹78 cr
Finance Costs₹7 cr
Depreciation & Amortisation₹28 cr
Other Expenses₹154 cr
Total Expenses₹336 cr
Profit before Tax₹61 cr
Tax Expense₹16 cr
Net Profit₹45 cr
Net margin on total income11.4%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹69 cr17.5%
Employee benefit expense₹78 cr19.6%
Finance costs₹7 cr1.7%
Depreciation & amortisation₹28 cr7.1%
Other expenses₹154 cr38.7%
Tax expense₹16 cr4.0%
Profit for the period₹45 cr11.4%
Total income ₹397 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue320 cr342 cr393 cr
Total income328 cr349 cr397 cr
Expenses271 cr297 cr336 cr
Profit before tax57 cr52 cr61 cr
Tax14 cr7 cr16 cr
Net profit (owners' share)45 cr45 cr47 cr
Net margin (owners' share, on revenue)14.2%13.1%12.0%
EPS (₹)4.714.934.88
YoY (latest quarter): total income +48.6% · net profit +12.0%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹2,282 cr
Shareholder equity
₹1,807 cr
parent shareholders
Total debt
₹253 cr
Cash
₹221 cr
Cash flow · H1 FY26
Operating
₹49 cr
Investing
₹-251 cr
Financing
₹14 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limited₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limited₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.05%
trailing 12 months
Dividend / share (TTM)
₹0.5
Last dividend
₹0.5
ex 14 Aug 2026
ActionDetailEx-date
Dividend₹0.5 / share14 Aug 2026
Who owns it · 2026-06-30
9.6% pledged
Promoter
55.8%
FII / Foreign
5.6%
DII / Domestic
10.8%
Retail / others
27.7%
Promoter stake down 10.5% over the last 12 quarters.
Smart-money activity
Bulk / block deals
short · NSE89 Sep 26
short · NSE63 Sep 26
short · NSE128 Aug 26
Stake changes
SoldDr. Neena Tyagi · promoter→ 0.62% · 56.34 L28 Nov 25
BoughtAjay Kumar Tyagi · promoter→ 30.59% · 2.00 L10 Feb 25
BoughtAjay Kumar Tyagi · promoter→ 31.59% · 50,00030 Nov 23
Promoter pledges
ReleasedJio Finance Ltd, IIFL Capital Services Ltd25.75 L · 8.85% held9 Dec 25
PledgedAditya Birla Finance Ltd, IIFL Finance Ltd, Jio Finance Ltd and Bajaj Finance Ltd82.02 L · 0.00% held27 Mar 25
What shareholders were asked to approve
1 proposal passed only on promoter votes

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 15 Jan 2026
See the official result
1
Appointment of Mr. Ramesh Krishnan (DIN: 06753052) as a non executive independent director for a term of five years
⚑ Passed only because promoters voted yes
Backed by 66% of shareholders other than promotersneeded 75%
96.27 L votes for, 49.44 L against · 34% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 4 named members
owning 55.8% between them · as of 2026-06-30
Ajay Kumar Tyagi30.59%
Kapil Kumar12.62%
Manju Tyagi11.96%
Neena Tyagi0.62%
Business done with them
FY2025 · 4 of the group
The company paid ₹5 cr to companies in the promoter group last year — about 0.6% of its ₹880 cr revenue.
Kapil Kumar
Other payments to them · Remuneration & Rent
also owns 12.62% of the company
₹1 cr
company paid
Ajay Kumar Tyagi
Other payments to them · Remuneration & Rent
also owns 30.59% of the company
₹1 cr
company paid
Manju Tyagi
Other payments to them · Remuneration
also owns 11.96% of the company
₹1 cr
company paid
Neena Tyagi
Other payments to them · Remuneration
also owns 0.62% of the company
₹1 cr
company paid

The company also transacted with 12 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.